Refractory Moderate To Severe Atopic Dermatitis In Adults And Pediatric Patients 12 Years Of Age And Older Not Adequately Controlled With Other Systemic Therapies — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for refractory moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies. 85 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
85
Active US patents
42/100
Avg vulnerability
$5.3B
Annual revenue covered

Originators in Refractory Moderate To Severe Atopic Dermatitis In Adults And Pediatric Patients 12 Years Of Age And Older Not Adequately Controlled With Other Systemic Therapies

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie Inc. 85 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating refractory moderate to severe atopic dermatitis in adults and pediatric patients 12 years of age and older not adequately controlled with other systemic therapies. Each bar = one year. Y-axis scaled to peak year (71 patents).

4
31
4
33
71
36
6
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Rinvoq
upadacitinib
 AbbVie Inc. 85 42 $5.3B 2031-01-15

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8962629 Rinvoq method of use 81 2031-01-15
8962629 Rinvoq method of use 76 2031-01-15
8962629 Rinvoq method of use 76 2031-01-15
11993606 Rinvoq method of use 75 2036-10-17
12365689 Rinvoq method of use 75 2036-10-17
11976077 Rinvoq method of use 75 2036-10-17
11993605 Rinvoq method of use 75 2036-10-17
12365689 Rinvoq method of use 75 2036-10-17
11512092 Rinvoq method of use 70 2036-10-17
11524964 Rinvoq method of use 70 2036-10-17

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
11186584 Rinvoq composition of matter 4 2036-10-17
9951080 Rinvoq composition of matter 4 2036-10-17
10981923 Rinvoq composition of matter 4 2036-10-17
RE47221 Rinvoq composition of matter 4 2033-08-16
11773105 Rinvoq composition of matter 12 2036-10-17
9951080 Rinvoq composition of matter 12 2036-10-17
11773105 Rinvoq composition of matter 12 2036-10-17
11718627 Rinvoq composition of matter 12 2036-10-17
11718627 Rinvoq composition of matter 12 2036-10-17
11680069 Rinvoq composition of matter 12 2036-10-17

Related